Pressmeddelande

BioStock: Full speed ahead for Elicera in 2024

Cision Publicerad: 19 Feb 08:34

Elicera Therapeutics has kicked off the year in boost mode. The Swedish cell and gene therapy company will get moving on the newly approved phase I/IIa study with lead CAR T candidate ELC-301, made possible by a major financing round coming later this month. Speaking to Elicera’s CEO Jamal El-Mosleh, it’s clear that the company is ready for a busy 2024, where now two pipeline candidates are in the clinic.

Read the full interview with Jamal El-Mosleh at biostock.se:

https://www.biostock.se/en/2024/02/full-speed-ahead-for-elicera-in-2024/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Nyheter om Elicera Therapeutics

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!